Racial differences in the relationship between hepatitis C infection and iron stores

Hepatology

Volumn 37, Issue 4, 2003, Pages 795-801

  Ioannou, George N ^a,b   Dominitz, Jason A ^a,b,d   Weiss, Noel S ^c   Heagerty, Patrick J ^c   Kowdley, Kris V ^a,e  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Veterans Puget Sound Health Care System   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

^e UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; LIVER ENZYME; TRANSFERRIN; VIRUS RNA;

ACADEMIC ACHIEVEMENT; ADULT; AFRICA; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; FERRITIN BLOOD LEVEL; GENDER; HEALTH SURVEY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; IRON STORAGE; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; NEGRO; PRIORITY JOURNAL; PUBLIC HEALTH; RACE DIFFERENCE; RISK FACTOR; WESTERN HEMISPHERE;

EID: 0037382796     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50147     Document Type: Article

References (50)

1. Howell C, Jeffers L, Hoofnagle JH. Hepatitis C in African Americans: summary ofa workshop. Gastroenterology 2000;119:1385-1396.
2. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. HEPATOLOGY 1999;30:787-793.
3. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, Fried MW, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. HEPATOLOGY 2001;33:433-438.
4. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-1680.
5. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-1492.
6. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-1432.
7. Piperno A, Vergani A, Malosio I, Parma L, Fossati L, Ricci A, Bovo G, et al. Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations. HEPATOLOGY 1998;28:1105-1109.
8. Riggio O, Montagnese F, Fiore P, Folino S, Giambartolomei S, Gandin C, Merli M, et al. Iron overload in patients with chronic viral hepatitis: how common is it? Am J Gastroenterol 1997;92:1298-1301.
9. Barbaro G, Di Lorenzo G, Ribersani M, Soldini M, Giancaspro G, Bellomo G, Belloni G, et al. Serum ferritin and hepatic glutathione concentrations in chronic hepatitis C patients related to the hepatitis C virus genotype. J Hepatol 1999;30:774-782.
10. Zein NN, Gross JB Jr, Poterucha JJ, Gossard AA, Wendt NK, Mitchell PS, et al. Significance of serum iron, iron saturation, and ferritin in patients infected with different hepatitis C genotypes [Abstract]. Gastroenterology 1995;108:1208A.
11. Andant CC, Lamoril J, Edery J, Barge J, Deybach JC, Devars du Mayne JF, Elzaabi M, et al. Hepatic iron concentration and serum iron parameters in patients with chronic hepatitis C [Abstract]. HEPATOLOGY 1996;24(Part 2):478A.
12. Sartori M, Andorno S, La Terra G, Boldorini R, Leone F, Pittau S, Zecchina G, et al. Evaluation of iron status in patients with chronic hepatitis C. Ital J Gastroenterol Hepatol 1998;30:396-401.
13. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992;102:2108-2113.
14. Barton AL, Banner BF, Cable EE, Bonkovsky HL. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am J Clin Pathol 1995;103:419-424.
15. Ikura Y, Morimoto H, Johmura H, Fukui M, Sakurai M. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. Am J Gastroenterol 1996;91:1367-1373.
16. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS. Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol 1994;20:410-415.
17. Olynyk JK, Reddy KR, Di Bisceglie AM, Jeffers LJ, Parker TI, Radick JL, Schiff ER, et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995;108:1104-1109.
18. Kageyama F, Kobayashi Y, Murohisa G, Shimizu E, Suzuki F, Kikuyama M, Souda K, et al. Failure to respond to interferon-alpha 2a therapy is associated with increased hepatic iron levels in patients with chronic hepatitis C. Biol Trace Element Res 1998;64:185-196.
19. Piperno A, Sampietro M, D'Alba R, Roffi L, Fargion S, Parma S, Nicoli C, et al. Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver 1996;16:248-254.
20. Izumi N, Enomoto N, Uchihara M, Murakami T, Ono K, Noguchi O, Miyake S, et al. Hepatic iron contents and response to interferon-alpha in patients with chronic hepatitis C. Relationship to genotypes of hepatitis C virus. Dig Dis Sci 1996;41:989-994.
21. Murakami CS, Wheeler D, Foster S, McIntire D, Cheng QC, Casey DL, Lee WM. Histology and hepatic iron content predict response to interferon in chronic hepatitis C [Abstract]. HEPATOLOGY 1995;22(Part 2):291A.
22. Clemente MG, Congia M, Lai ME, Lilliu F, Lampis R, Frau F, Frau MR, et al. Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. J Pediatr 1994;125:123-128.
23. National Center for Health Statistics. Plan and Operation of the Third National Health and Nutritin Examination Survey, 1988-1994. Hyatsville: National Center for Health Statistics; 1994.
24. Coder SJ, Bronner MP, Press RD, Carlson TH, Perkins JD, Emond MJ, Kowdley KV. End-stage liver disease without hemochromatosis associated with elevated hepatic iron index. J Hepatol 1998;29:257-262.
25. Ludwig J, Hashimoto E, Porayko MK, Moyer TP, Baldus WP. Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology 1997; 112:882-888.
26. Deugnier Y, Turlin B, le Quilleuc D, Moirand R, Loreal O, Messner M, Meunier B, et al. A reappraisal of hepatic siderosis in patients with end-stage cirrhosis: practical implications for the diagnosis of hemochromatosis. Am J Surg Pathol 1997;21:669-675.
27. Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat 1997;4:199-208.
28. Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1997;92:1302-1304.
29. Gunter EW, Lewis BG, Koncikowski SM. Laboratory procedures used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994. Hyattsville: Centers for Disease Control and Prevention, 1996.
30. Looker AC, Gunter EW, Johnson CL. Methods to assess iron status in various NHANES surveys. Nutr Rev 1995;53:246-254.
31. Nainan OV, Cromeans TL, Margolis HS. Sequence-specific, single-primer amplification and detection of PCR products for identification of hepatitis viruses. J Virol Methods 1996;61:127-134.
32. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-562.
33. Looker AC, Dallman PR, Carroll MD, Gunrer EW, Johnson CL. Prevalence of iron deficiency in the United States. JAMA 1997;277:973-976.
34. Looker AC, Johnson CL. Prevalence of elevated serum transferrin saturation in adults in the United States. Ann Intern Med 1998;129:940-945.
35. Baer DM, Simons JL, Staples RL, Rumore GJ, Morton CJ. Hemochromatosis screening in asymptomatic ambulatory men 30 years of age and older. Am J Med 1995;98:464-468.
36. Asberg A, Hveem K, Thorstensen K, Ellekjter E, Kannelonning K, Fjosne U, Halvorsen TB, et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 2001;36:1108-1115.
37. Guyatt GH, Oxman AD, Ali M, Willan A, McIlroy W, Patterson C. Laboratory diagnosis of iron-deficiency anemia: an overview. [erratum appears in J Gen Intern Med 1992;7:423]. J Gen Intern Med 1992;7:145-53.
38. Di Bisceglie AM, Bonkovsky HL, Chopra S, Flamm S, Reddy RK, Grace N, Killenberg P, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. HEPATOLOGY 2000;32:135-138.
39. Fontana RJ, Israel J, LeClair P, Banner BF, Tortoretli K, Grace N, Levine RA, et al. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. HEPATOLOGY 2000;31:730-736.
40. Guyader D, Boucher E, Andre P, Even C, Cottereau J, Bianchi A, Gasser P, et al. A pilot study of iron depletion as adjuvant therapy in chronic hepatitis C patients not responding to interferon. Am J Gastroenterol 1999;94:1696-1698.
41. Fong TL, Han SH, Tsai NC, Morgan TR, Mizokami M, Qian D, Phan C, et al. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C. J Heparol 1998;28:369-374.
42. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994;89:986-988.
43. Van Thiel DH, Friedlander L, Molloy PJ, Kania RJ, Fagiuoli S, Wright HI, Gasbarrini A, et al. Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy. Hepatogastroenterology 1996;43:1557-1561.
44. Pianko S, McHutchison JG, Gordon SC, Heaton S, Goodman ZD, Patel K, Cortese CM, et al. Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection. J Interferon Cytokine Res 2002;22:483-489.
45. Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, Lecis E, Burra P, et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995;22:449-456.
46. Bacon BR, Btitton RS. Hepatic injury in chronic iron overload. Role of lipid peroxidation. Chem Biol Interact 1989;70:183-226.
47. Chapoutot C, Esslimani M, Joomaye Z, Ramos J, Perney P, Laurent C, Fabbro-Peray P, et al. Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis. Gut 2000;46:711-714.
48. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002;35(Suppl):S72-S78.
49. Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol 2002;97:700-706.
50. Haque S, Chandra B, Gerber MA, Lok AS. Iron overload in patients with chronic hepatitis C: a clinicopathologic study. Hum Pathol 1996;27:1277-1281.